Tag: NVIDIA

  • Overbought Stocks: NVIDIA Corporation (NASDAQ:NVDA), Novo Nordisk (NYSE:NVO), Illumina, Inc. (NASDAQ:ILMN), Forest Laboratories (NYSE:FRX)

    NVIDIA Corporation (NASDAQ:NVDA) Saw its net income from its fourth quarter operations slide down to $147 million as against the $147 million it had managed to generate in 4Q12. Earnings per share for 4Q were down to 25 cents as against the 28 cents it had achieved in 4Q12. Revenue came in at $1.14 billion for the quarter, which was a slight 3.4 percent increase over last Q4. Gross margins for the 4Q came in at 54.1 percent, which was almost flat when compared to 4Q12. NVIDIA Corporation (NASDAQ:NVDA) stock opened at $17.90 in last session, and closed at $18.14, while the day range of NVDA stock is $6.08-$7.00.The stock showed a positive weekly performance of 11.63%.

    Novo Nordisk A/S (ADR) (NYSE:NVO) Zacks lowered shares of Novo Nordisk (NYSE:NVO) from an outperform rating to a neutral rating in a report released on Monday, AnalystRatingsNetwork.com reports. Zacks currently has $45.00 price objective on the stock. Novo Nordisk A/S (ADR) (NYSE:NVO)  stock opened at $44.19, in last session and closed at $44.09, by loosed -0.54%.The 52 week range was $29.90-$44.57.Company’s market capitalization is $117.09 billion.

    Illumina, Inc. (NASDAQ:ILMN) The company announced that it will webcast its presentation at the Cowen and Company 34th Annual Health Care Conference in Boston, Massachusetts, on March 5, 2014. The live webcast is scheduled to begin at 8:40 AM ET and will feature a brief overview of the company by Marc Stapley, Senior Vice President and Chief Financial Officer, followed by a question and answer session. Illumina, Inc. (NASDAQ:ILMN) stock loosed -0.14% and finished the last session at $170.16.The EPS of the stock remained 0.83.Company’s market capitalization is $21.51 billion.

    Forest Laboratories, Inc. (NYSE:FRX) On Tuesday Irish drug maker Actavis PLC (NYSE: ACT), producer of generic and specialty urology and women’s health products, agreed to buy New York-based Forest Laboratories Inc. (NYSE: FRX) for $25 billion. Forest Laboratories, Inc. (NYSE:FRX) stock opened the session at $91.65, and closed the session at $93.98. The 52 week range of the FRX stock remained $35.22-$94.68 and the day range was $91.35-$94.68.